U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 ...

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for:

Related Keywords

United States ,Ilya Rachman ,Gabriel Morris ,Mike Moyer ,Los Angeles ,Immix Biopharma Inc ,Nasdaq ,Nexcella Inc ,Exchange Commission ,Office Of Orphan Products Development ,Company Contact ,Drug Administration ,Drug Designation ,Prescription Drug User Fee ,Multiple Myeloma ,Orphan Drug Designation ,Orphan Products Development ,Immix Biopharma Chief Executive ,Immix Biopharma Chief Financial Officer ,Immix Biopharma ,Tissue Specific Therapeutic ,Rare Pediatric Disease Designation ,Orphan Drug ,Risk Factor ,Annual Report ,Region ,